DDW Editor Reece Armstrong speaks to Dr. Zachary Gurard-Levin is the CEO and Founder of Peapod Bio about challenges in small molecule drug discovery and what technologies are advancing this sector. RA: What are the biggest challenges facing small molecule drug discovery and development? ZG: The… Read More
Bio-Techne has opened a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for… Read More
Michelle L. Mellion, MD, Chief Medical Officer at AstronauTx discusses why small molecules that can restore deep, restorative sleep, could be key to cognitive diseases such as Alzheimer’s. Sleep is the bedrock of good brain health. For a long time, the focus has been on the quantity of sleep. A large body of evidence has… Read More
Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More
Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More
Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. The webinar will take place on 10 November, 8am PST / 11am EST / 4PM GMT / 5PM CET. Using its ‘Every Compound… Read More
Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding. Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules… Read More
Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar on 10 November 2025 will explore the… Read More
Join this free webinar, hosted by DDW, to learn how Evotec is planning to shorten timelines for small molecule drug discovery projects. Using its ‘Every Compound a Candidate (ECC)’ approach, Evotec is aiming to reduce timelines to under two years. This webinar will explore the current challenges facing small molecule… Read More
US President Trump has signed an executive order designed to lower the cost of prescription drug prices, which includes a win for manufacturers of small molecule drugs. The order comes one day after the Trump administration instituted a national security report into the pharmaceutical industry, which is… Read More
Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More
Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More
Eleven drugs are projected to achieve blockbuster status or revolutionise treatment paradigms within five years, according to Clarivate’s 2025 Drugs to Watch report. The drugs address critical challenges in areas such as obesity, oncology, and gene therapy, and are forecast to achieve blockbuster sales by 2030 or… Read More
Jason Park, Ph.D, CEO & Co-Founder of Empress Therapeutics and Operating Partner, Flagship Pioneering, examines why technologies such as artificial intelligence (AI) and machine learning (ML) will prove essential… Read More
Yunovia (a subsidiary of Ildong Pharmaceutical Group) has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes. The Phase I Multiple Ascending Dose (MAD)… Read More
Serna Bio was founded by Rabia Khan, who is also the CEO, to unlock the transcriptome as a drug discovery target. DDW’s Megan Thomas speaks to Khan about the work her team is doing to create the first map of the druggable transcriptome, which involves understanding RNA biology to discover… Read More
